A. Thompson

发表

Selective organ preservation with neo-adjuvant chemotherapy for the treatment of muscle invasive transitional cell carcinoma of the bladder

R. Eeles, D. Dearnaley, A. Horwich, 2015, British Journal of Cancer.

Selective organ preservation with neo-adjuvant chemotherapy for the treatment of muscle invasive transitional cell carcinoma of the bladder

R. Eeles, D. Dearnaley, A. Horwich, 2015, British Journal of Cancer.

Selective organ preservation with neo-adjuvant chemotherapy for the treatment of muscle invasive transitional cell carcinoma of the bladder

R. Eeles, D. Dearnaley, A. Horwich, 2015, British Journal of Cancer.

Comprehensive multiplexed immune profiling of the ductal carcinoma in situ immune microenvironment regarding subsequent ipsilateral invasive breast cancer risk

Fei Yang, A. Broeks, I. Wistuba, 2022, British Journal of Cancer.

Successful Patient Acceptance of Randomization Within the Pace Study (Prostate Advances in Comparative Evidence)

I. Kaplan, N. V. As, M. Sanda, 2013 .

Molecular classification and biomarkers of clinical outcome in breast ductal carcinoma in situ: Analysis of TBCRC 038 and RAHBT cohorts.

Kathleen E. Houlahan, Tyler T. Risom, R. Tibshirani, 2022, Cancer cell.

Learning to distinguish progressive and non-progressive ductal carcinoma in situ

N. Navin, S. Nik-Zainal, H. Davies, 2022, Nature Reviews Cancer.

Mouse‐INtraDuctal (MIND): an in vivo model for studying the underlying mechanisms of DCIS malignancy

S. Hilsenbeck, A. Godwin, Jianhua Zhang, 2021, The Journal of pathology.

Cohort profile of the Sloane Project: methodology for a prospective UK cohort study of >15 000 women with screen-detected non-invasive breast neoplasia

E. Provenzano, S. Pinder, M. Wallis, 2022, BMJ Open.

Unresected screen-detected ductal carcinoma in situ: Outcomes of 311 women in the Forget-Me-Not 2 study

E. Provenzano, S. Pinder, M. Wallis, 2022, Breast.

Long-term risk of subsequent ipsilateral lesions after surgery with or without radiotherapy for ductal carcinoma in situ of the breast

E. Hwang, M. Schmidt, E. Sawyer, 2021, British Journal of Cancer.

Management and 5-year outcomes in 9938 women with screen-detected ductal carcinoma in situ: the UK Sloane Project.

G. Ball, S. Lakhani, S. Pinder, 2018, European journal of cancer.

Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial

G. Rodrigues, J. Staffurth, T. Tsakiridis, 2019, The Lancet. Oncology.

“Is it cancer or not?” A qualitative exploration of survivor concerns surrounding the diagnosis and treatment of ductal carcinoma in situ

E. Hwang, J. Gierisch, D. Collyar, 2022, Cancer.

Archival single-cell genomics reveals persistent subclones during DCIS progression

P. Kristel, N. Navin, Lorraine M. King, 2023, Cell.

Molecular classification and biomarkers of clinical outcome in breast ductal carcinoma in situ: Analysis of TBCRC 038 and RAHBT cohorts

Kathleen E. Houlahan, Tyler T. Risom, R. Tibshirani, 2023, Cancer cell.

Surveillance Imaging after Primary Diagnosis of Ductal Carcinoma in Situ.

Lars J. Grimm, W. V. van Harten, E. Hwang, 2023, Radiology.